Contribute Try STAT+ Today

Vertex Pharmaceuticals (VRTX) reached an agreement Wednesday with the Food and Drug Administration that shaves nine months off the length of its next pivotal cystic fibrosis clinical trial.

The speedy trial design means the first of Vertex’s three-drug regimens for cystic fibrosis could have top-line results by the end of this year or early in 2019 — faster than anticipated. The company’s accelerated timeline also makes it harder for any of its cystic fibrosis competitors to keep pace.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy